Online Meeting
2022.08.27
Recently, the 2022 China Medical Equipment Association Ophthalmology Branch Committee and the Chinese Journal of Ophthalmology Editorial Committee jointly organized the Annual Meeting of the China Medical Equipment Association Ophthalmology Branch Committee and the Chinese Journal of Ophthalmology (Electronic Edition), as well as the Eye Technology and Equipment Exhibition, which was successfully held online.
The conference invited well-known domestic experts and scholars in the field of ophthalmology to give high-quality academic reports on medical equipment ophthalmic technology innovation, industry development, and clinical application. The conference aimed to showcase the latest technologies, exchange ideas on discipline construction, and share work experiences.
Professor Chen Xinjian, founder of Big Vision Medical Technology, was invited to participate in the conference and gave a theme presentation on “Fully Automatic AI Ophthalmic OCT”, where he provided detailed introduction on the latest research achievements of artificial intelligence in the field of ophthalmic OCT and the conversion application results of Big Vision Medical Technology to conference attendees.
In the report, Professor Chen introduced that based on solid scientific research strength, Big Vision Medical Technology has made practical efforts to promote the deep integration of industry, academia and research, and independently developed a new generation of fully automatic AI OCT (BV1000). Different from traditional OCT, it achieves automatic pupil positioning and focusing, full-process voice guidance, and system-assisted diagnosis for 16 main eye diseases including choroidal neovascularization, macular edema, vitreous opacities, and macular hole. It also identifies and automatically annotates disease lesions, reducing the pain points of inefficient manual operation due to lack of skill and unbalanced primary eye medical resources. It provides valuable diagnostic and therapeutic information for grassroots ophthalmologists, serving the clinical diagnosis and treatment needs of hundreds of millions of eye disease patients in China.
In recent years, China’s prevention and control of myopia in children and adolescents has received high attention from the government, schools, parents, and medical institutions. Relevant research has shown that choroidal thickness is an important indicator for evaluating the development of myopia. Various recognized effective methods for preventing and controlling myopia (such as low-concentration atropine and orthokeratology lenses) have a significant choroidal thickening effect.
Big Vision Medical Technology has developed an advanced AI algorithm for OCT choroidal automatic segmentation and thickness measurement. This can automatically segment the choroid and measure its thickness, providing valuable reference for scientifically formulating myopia intervention measures.
Big Vision Medical Technology has always been committed to the scientific research innovation and clinical application of ophthalmic AI. It has obtained more than 80 innovative achievements, patents, and the highest award in the field of artificial intelligence- the first prize of the Wu Wenjun Artificial Intelligence Technology Invention Award. The company has published over 150 papers in international and domestic authoritative journals. Significant achievements have been made in technology transfer, making it a truly intelligent and efficient AI assistant for ophthalmologists.
The successful holding of this conference has greatly promoted the new round of intelligent medical diagnosis and treatment technology and cutting-edge academic exchanges. As a leader in China’s ophthalmic artificial intelligence field, Big Vision Medical Technology will continue to forge ahead on the path to achieving the goal of national eye health. We will contribute to the cause of building a healthy China with advanced ophthalmic AI technology.
No comments yet.